TABLE 4

Follow-up Results

Short-term follow-up
 AgeMean 6.12 mo (SD 2.1 mo)
 Died (not related to stroke)2 (2%)
 Lost to follow-up11 (11%)
 Follow-up available87 (89% of survivors)
 Motor abnormality35/87 (40%)
  Unilateral spastic movement disorder31/87 (36%)
  Bilateral spastic movement disorder4/87 (4%)
 Antiepileptic medication17/87 (19%)
  Antiepileptic medication discontinued thereafter11/87 (12%)
  Antiepileptic medication continued6/87 (7%)
Medium-term follow-up
 AgeMean 23.3 mo (SD 4.3 mo)
 Died (not related to stroke)2 (2%)
 Refused participation4 (4%)
 Moved to foreign country1 (1%)
 Lost to follow-up20 (20%)
 Follow-up available74 (76% of survivors)
 Cerebral palsy29/74 (39%)
  Unilateral spastic cerebral palsy23/74 (31%) (all GMFCS I–II)
  Bilateral spastic cerebral palsy4/74 (5%) (all GMFCS III–V)
  Ataxic cerebral palsy2/74 (3%) all GMFCS I or II)
 BSID-II MDI (n = 62)Mean 91.5 (range 49–119, SD 18.7)
  Normal performance (MDI 85–115)43/62 (69%)
  Mildly delayed performance (MDI 70–84)13/62 (21%)
  Significantly delayed performance (MDI <70)6/62 (10%)
 Epilepsy7/74 (9%)
  Antecedent of infantile spasms4/74 (5%)
  Symptomatic epilepsy with focal or generalized seizures3/74 (4%)